Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 4Stomach Neoplasms 2Carcinoma, Hepatocellular 2Rectal Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Pancreatic Adenocarcinoma Metastatic 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1Esophageal Squamous Cell Carcinoma 1Digestive System Diseases 1Carcinoma 1Advanced Pancreatic Cancer 1

Interventions

Gemcitabine 9130-nm albumin-bound paclitaxel 6S 1 (combination) 4Albumin-Bound Paclitaxel 4toripalimab 3Taxes 3Nivolumab 2Injections 2Drug Therapy 2surufatinib 1penpulimab 1pegylated granulocyte colony-stimulating factor 1paricalcitol 1nimotuzumab 1irinotecan sucrosofate 1gimeracil 1fluzoparib 1envafolimab 1endostar protein 1conteltinib 1camrelizumab 1cabiralizumab 1apatinib 1Tegafur 1Simvastatin 1Radiosurgery 1Paclitaxel 1Oxaliplatin 1Metformin 1Leucovorin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Pancreatic Cancer × penpulimab × Gastrointestinal × Clear all
NCT06821503 2026-03-10

Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1/2 Recruiting
72 enrolled
Gastrointestinal

Advanced Pancreatic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡